Waste Connections On Pace for Record High Close — Data Talk
Waste Connections, Inc. (WCN) is currently at $162.65, up $6.10 or 3.9%
--Would be new all-time high (Based on available data back to June 5, 2009)
--On pace for largest percent increase since Nov. 3, 2022, when it rose 6.57%
--Currently up three of the past four days
--Currently up two consecutive days; up 5.36% over this period
--Best two day stretch since the two days ending Nov. 3, 2022, when it rose 5.81%
--Up 4.76% month-to-date
--Up 8.96% year-to-date
--Up 20.01% from 52 weeks ago (Feb. 15, 2023), when it closed at $135.53
--Would be a new 52-week closing high
--Up 27.19% from its 52-week closing low of $127.88 on Oct. 26, 2023
--Traded as high as $162.79; new all-time intraday high (Based on available data back to June 5, 2009)
--Up 3.99% at today's intraday high; largest intraday percent increase since Nov. 14, 2023, when it rose as much as 4.06%
All data as of 1:21:49 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
February 14, 2024 13:38 ET (18:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track